Using a DNA vaccine to stop multiple myeloma from developing
Targeting DKK1 with a DNA Vaccine to Prevent Development of Multiple Myeloma
This study is testing a new vaccine that aims to help people with early signs of multiple myeloma, like MGUS and smoldering multiple myeloma, by training their immune system to fight off cancer cells more effectively and potentially avoid harsher treatments.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10874135 on NIH RePORTER |
What this research studies
This research focuses on preventing the progression of multiple myeloma, a type of blood cancer, by targeting a specific protein called DKK1 with a DNA vaccine. The study aims to develop a novel immunoprevention strategy for patients who have precursors to multiple myeloma, such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). By utilizing a vaccine approach, the researchers hope to stimulate the immune system to recognize and attack cells expressing DKK1, which is prevalent in these early stages of the disease. This could lead to less toxic treatment options compared to traditional chemotherapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with MGUS or smoldering multiple myeloma who are at risk of progressing to multiple myeloma.
Not a fit: Patients who have already been diagnosed with overt multiple myeloma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new way to prevent multiple myeloma from developing in at-risk patients.
How similar studies have performed: Previous research has shown promise in targeting DKK1 for cancer treatment, indicating potential success for this novel approach.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Wu, Xiangwei — University of Tx Md Anderson Can Ctr
- Study coordinator: Wu, Xiangwei
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.